A recent study by The George Institute and Imperial College London highlights the exclusion of women from heat adaptation ...
The ICMR has funded the IPIROC study to evaluate a cost-effective dosing strategy for PARP inhibitor rucaparib in ovarian cancer patients, aiming to enhance access and reduce side effects.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback